|Videos|September 22, 2021

Dr. Shore on the benefits of starting darolutamide for patients with nmCRPC

“The take-home message for all practicing urologists should be that if you have an nmCRPC patient, don't wait for them to develop mCRPC based on conventional imaging…We have 3 really efficacious level 1 evidence studies that have demonstrated the value for starting any of these 3 drugs,” says Neal D. Shore, MD.

In this video, Neal D. Shore, MD, FACS, advises clinicians to counsel their patients with nmCRPC about starting the darolutamide (Nubeqa) regimen, as it has many benefits that will improve their quality of life. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME